Posted by Michael Wonder on 17 Jun 2026
Qihan Biotech's QT-019B Receives FDA RMAT and BTD
16 June 2026 - Hangzhou Qihan Biotech today announced that its internally developed universal dual-target CAR-T therapy, QT-019B, has officially received both regenerative medicine advanced therapy designation and breakthrough therapy designation from the US FDA.
This achievement marks another significant milestone for QT-019B following its receipt of fast track designation from the FDA in November 2025.
